Brought to you by 
Aadi Bioscience raises $23mm in Series A round
09 May 2017
Executive Summary
Aadi Bioscience Inc. (oncology- and cardiovascular-focused biopharma) raised $23mm in its Series A financing round led by Hermed Capital and with participation from Celgene Corp., Vivo Capital, Decheng Capital, the Helsinn Investment Fund, and Star Summit Ventures. Carlo Montagner (Specialised Therapeutics), Richard Maroun (Frazier Healthcare Partners), Jerry Xiao (Hermed Capital), and Mahendra Shah (Vivo Capital) joined the company's board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aadi Bioscience raises $23mm in Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice